Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study

INTRODUCTION: Previous trials demonstrated that anti-angiogenesis or anti-programmed death protein 1 (PD-1) monotherapy showed unsatisfied effect in advanced hepatocellular carcinoma (HCC). No study existed that focus on the effects of camrelizumab and apatinib (“C+A”) combination therapy for HCC pa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Onco Targets Ther
Main Authors: Yuan, Guosheng, Cheng, Xiao, Li, Qi, Zang, Mengya, Huang, Wei, Fan, Wenzhe, Wu, Tao, Ruan, Jian, Dai, Wencong, Yu, Wenxuan, Chen, Mian, Guo, Yabing, Hu, Xiaoyun, Chen, Jinzhang
Formato: Artigo
Idioma:Inglês
Publicado: Dove 2020
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7734076/
https://ncbi.nlm.nih.gov/pubmed/33328740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S286169
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares